| Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (NCT05232071) | Inventiva Pharma | 2022-06-29 |
| DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis (NCT05415722) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-06-28 |
| A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH (NCT03970031) | Cirius Therapeutics, Inc. | 2022-06-01 |
| Nonalcoholic Fatty Liver Disease in HIV Database (NCT05023044) | Johns Hopkins University | 2022-05-12 |
| Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis (NCT05284448) | Al-Azhar University | 2022-02-01 |
| Novel MRE Technique to Assess a Risk Factor for Liver Cancer (NCT05165446) | Natalie Torok | 2022-01-27 |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) (NCT04697810) | Can-Fite BioPharma | 2021-12-10 |
| Characterization of the Platelet Inflammatory Response in NAFL and NASH (NCT05128253) | Stefania Basili | 2021-12-06 |
| Estrogen Administration for the Treatment of NASH in Postmenopausal Women (NCT04833140) | Massachusetts General Hospital | 2021-12-02 |
| A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia (NCT05090111) | Aligos Therapeutics | 2021-12-01 |
| Phase 2a Study of HPG1860 in Subjects With NASH (NCT05338034) | Hepagene (Shanghai) Co., Ltd. | 2021-11-22 |
| Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach (NCT04841057) | University of Missouri-Columbia | 2021-11-01 |
| Pemvidutide (ALT-801) DDI Study in Healthy Volunteers (NCT04972396) | Altimmune, Inc. | 2021-09-15 |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NCT04849728) | Inventiva Pharma | 2021-08-19 |
| PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis (NCT05022693) | 89bio, Inc. | 2021-08-16 |
| A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) (NCT05039450) | Akero Therapeutics, Inc | 2021-07-30 |
| A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects. (NCT04808154) | Sinew Pharma Inc. | 2021-07-22 |
| Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis (NCT03587831) | University of Minnesota | 2021-07-01 |
| Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) (NCT04929483) | 89bio, Inc. | 2021-06-04 |
| THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis) (NCT04925362) | Assistance Publique - Hôpitaux de Paris | 2021-06-01 |
| AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NCT04897594) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2021-05-20 |
| Gut Permeability and Bariatric-metabolic Surgery (NCT05257200) | Medical University of Vienna | 2021-05-01 |
| Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers (NCT04874233) | Rivus Pharmaceuticals, Inc. | 2021-04-19 |
| Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease (NCT04576923) | Indiana University | 2021-03-19 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. (NCT05441904) | Poxel SA | 2021-03-08 |
| Study to Evaluate MET642 in Patients With NASH (NCT04773964) | Metacrine, Inc. | 2021-03-03 |
| Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH (NCT03538236) | Johns Hopkins University | 2021-03-01 |
| Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE (NCT04591106) | University of California, Los Angeles | 2021-02-17 |
| A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (NCT04767529) | Akero Therapeutics, Inc | 2021-02-16 |
| Multiple Ascending Dose Study of HU6 in High BMI Volunteers (NCT04709913) | Rivus Pharmaceuticals, Inc. | 2021-01-04 |
| Liquid Biopsy for NASH and Liver Fibrosis (NCT04677101) | Catholic University of the Sacred Heart | 2020-12-16 |
| Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH (NCT04702490) | Metacrine, Inc. | 2020-12-15 |
| Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism (NCT04395950) | Columbia University | 2020-12-01 |
| A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) (NCT04618744) | Oramed, Ltd. | 2020-11-24 |
| NASH in Subjects With Different Classes of Obesity (NCT04653103) | Catholic University of the Sacred Heart | 2020-11-20 |
| A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial (NCT04685993) | Lipocine Inc. | 2020-11-11 |
| Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) (NCT04321343) | Poxel SA | 2020-09-01 |
| Ascending Dose Study of HU6 in Healthy Volunteers (NCT04463017) | Rivus Pharmaceuticals, Inc. | 2020-08-12 |
| Non-Invasive Quantification of Liver Health in NASH (N-QUAN) (NCT04054310) | Perspectum | 2020-08-05 |
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NCT04365868) | Galectin Therapeutics Inc. | 2020-06-25 |
| Evaluation of an Endoscopic Sutured Gastroplasty in Patients With NonAlcoholic Steatohepatitis (NASH) and Fibrosis. (NCT04653311) | Erasme University Hospital | 2020-06-23 |
| A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects (NCT04480710) | Hepion Pharmaceuticals, Inc. | 2020-06-23 |
| LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) (NCT04328077) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-06-18 |
| Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment (NCT04308980) | Russian Academy of Medical Sciences | 2020-03-20 |
| Effects of Plant Sterols and Stanols on Liver Inflammation (NCT05037890) | Maastricht University Medical Center | 2020-02-20 |
| Bariatric Surgery vs. Lifestyle Modification for NASH (NCT04298736) | Hospital de Clinicas de Porto Alegre | 2020-02-19 |
| Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat (NCT04240145) | Gehad Abd Elaziz Mhmoud Ahmad | 2020-02-01 |
| NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL) (NCT03968354) | Assistance Publique - Hôpitaux de Paris | 2020-02-01 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects (NCT04146805) | Blade Therapeutics | 2020-01-10 |
| Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients (NCT04561895) | Cairo University | 2020-01-01 |
| Curcumin for Pediatric Nonalcoholic Fatty Liver Disease (NCT04109742) | Columbia University | 2019-12-09 |
| A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (NCT04173065) | Viking Therapeutics, Inc. | 2019-11-15 |
| NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal (NCT03864835) | Milton S. Hershey Medical Center | 2019-11-01 |
| Tocotrienol Against the Progression of End Stage Liver Disease (NCT02581085) | Chandan Sen | 2019-11-01 |
| Vitamin E for NASH Treatment in HIV Infected Individuals (NCT03669133) | Indiana University | 2019-10-01 |
| LITMUS Imaging Study (NCT05479721) | University of Oxford | 2019-09-04 |
| PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies (NCT04371042) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2019-09-01 |
| Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) (NCT03648554) | Central Hospital, Nancy, France | 2019-09-01 |
| Hepatic Energy Fluxes in NASH and NAS Patients (NCT03997422) | University of Minnesota | 2019-07-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients (NCT03976687) | Enyo Pharma | 2019-06-11 |
| A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (NCT03976401) | Akero Therapeutics, Inc | 2019-05-28 |
| Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver Health" (NCT03897218) | RWTH Aachen University | 2019-05-20 |
| Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3) (NCT03912532) | NGM Biopharmaceuticals, Inc | 2019-05-16 |
| Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients (NCT03963921) | Cellaion SA | 2019-04-09 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (NCT03900429) | Madrigal Pharmaceuticals, Inc. | 2019-03-28 |
| Hepaxa Management of Non-alcoholic Fatty Liver Disease (NCT03801577) | BASF AS | 2019-02-01 |
| Spironolactone Therapy In Young Women With NASH (NCT03576755) | University of California, San Francisco | 2019-01-09 |
| Omega-3 vs Very Low Calorie Diet for Liver Size Reduction (NCT03132662) | McMaster University | 2019-01-01 |
| Mechanism of DCs Dysfunction in Chronic HBV Infection (NCT03753308) | University Hospital, Grenoble | 2018-12-05 |
| Splanchnic and Systemic VLDL-TG and FFA Balance (NCT04292977) | University of Aarhus | 2018-12-01 |
| A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations (NCT03726827) | Fatty liver Foundation | 2018-12-01 |
| Effects of Exercise on VLDL-TG Metabolism (NCT03678727) | University of Aarhus | 2018-12-01 |
| A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects (NCT03783897) | Enanta Pharmaceuticals, Inc | 2018-11-27 |
| Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects (NCT04643795) | Madrigal Pharmaceuticals, Inc. | 2018-10-25 |
| Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects (NCT03748628) | Enanta Pharmaceuticals, Inc | 2018-10-05 |
| Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis (NCT04066400) | Johannes Gutenberg University Mainz | 2018-10-01 |
| Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers (NCT03610945) | Enanta Pharmaceuticals, Inc | 2018-07-19 |
| Mild Hypothermia and Acute Kidney Injury in Liver Transplantation (NCT03534141) | University of California, San Francisco | 2018-07-07 |
| A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients (NCT03472157) | University Hospital, Lille | 2018-06-20 |
| The Liver in the World Trade Center Health Program General Responder Cohort and Controls (NCT03858920) | Icahn School of Medicine at Mount Sinai | 2018-05-08 |
| Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials (NCT03611101) | Meridian Bioscience, Inc. | 2018-05-04 |
| A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) (NCT03551522) | Gilead Sciences | 2018-04-30 |
| Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH (NCT03490370) | NHS Tayside | 2018-04-03 |
| Study of Gemcabene in Adults With FPLD (NCT03508687) | Elif Oral | 2018-03-13 |
| The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology (NCT03294941) | HepQuant, LLC | 2017-12-08 |
| Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH (NCT03332940) | Navidea Biopharmaceuticals | 2017-12-06 |
| Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM (NCT03291249) | Tiziana Life Sciences LTD | 2017-12-01 |
| Effect of DMR in the Treatment of NASH (NCT03536650) | Erasme University Hospital | 2017-11-08 |
| Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan (NCT03289897) | Perspectum | 2017-09-05 |
| An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD (NCT03868566) | Sinew Pharma Inc. | 2017-08-04 |
| Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers (NCT03213145) | Enanta Pharmaceuticals, Inc | 2017-07-11 |
| A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH (NCT02784444) | Cirius Therapeutics, Inc. | 2016-09-14 |
| Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14 (NCT03439189) | Meridian Bioscience, Inc. | 2016-08-28 |
| The European NAFLD Registry (NCT04442334) | Newcastle University | 2015-05-01 |
| Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study (NCT04306939) | University of Pittsburgh | 2014-11-01 |
| Disease Prevention in Clinical Practice Base on Patient Specific Physiology (NCT03308773) | Pacific Coast Family Medical Group | 2009-01-05 |
| Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (NCT00678587) | GlaxoSmithKline | 2008-06-01 |